Fred and Marthambles- The Ph1 VK2735 oral data was over 28 days or 4 weeks. I've posted a graph of the results on WL within this message. The 8% WL figure is correct and for the 100mg dose. Since N was small, you really can't use this data to get a WL estimate for ph2 accurately. (I especially think the 100 mg dose got unrealistically high WL).
I've already posted here that I expect ORAL tolerability to be "Best In Class" and that WL will be "Stellar." (see #msg-176446318 ) If you are looking for a WL number estimate, I will say that it will be double digit at the highest dose of 120 mg approaching the ph2 SC trial results of 13% over 13 wks. (pure SPECULATION on my part- do your own DD as I could be off). Having said that, the more important results will be the 60 mg dose and the 90mg "maintenance" dose in my view (the one that steps up to 90mg and comes down to 30mg). Both of these dosing schemes would be competitive in an induction setting if they were to get close to double digit WL using my cost estimates on API (which I have yet to post).
Market Data 
Markets 
AI
